GKOS
Glaukos Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 125 | +9 | 42.85M | $5.95B | +15 | −5 |
| Q1 2026 | 118 | -1 | 46.55M | $5.02B | +6 | −8 |
| Q4 2025 | 118 | 0 | 48.22M | $5.44B | +2 | −1 |
| Q3 2025 | 22 | +5 | 29.69M | $2.42B | +5 | −1 |
| Q2 2025 | 15 | -2 | 32.65M | $3.37B | +1 | −3 |
| Q1 2025 | 14 | -2 | 8.81M | $867.57M | +1 | −3 |
| Q4 2024 | 16 | -1 | 9.74M | $1.46B | — | −1 |
| Q3 2024 | 16 | 0 | 7.06M | $919.99M | +1 | −1 |
| Q2 2024 | 16 | — | 6.75M | $798.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 1.28M | — | $151.24M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 1.28M | — | $151.24M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | PRIMECAP Management ✦ | 1.22M | — | $144.48M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.11M | — | $130.91M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.11M | — | $130.91M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 570.00K | — | $67.46M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 553.50K | — | $65.51M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 553.50K | — | $65.51M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 553.50K | — | $65.51M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 553.50K | — | $65.51M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Capital World Investors ✦ | 550.32K | — | $65.13M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 537.97K | — | $63.67M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 528.73K | — | $62.58M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 200.00K | — | $23.67M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 121.89K | — | $14.43M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 32.64K | — | $3.86M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 27.36K | — | $3.24M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 27.36K | — | $3.24M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 9.23K | — | $1.09M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | GAMCO Investors ✦ | 5.51K | — | $651,753 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 4.14K | — | $490,087 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 4.14K | — | $490,087 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 2.41K | — | $284,868 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 57.55M shares, $6.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.50K sh · $475,000
Officer · 27.96K sh · $5.00M
Officer · 32.04K sh · $5.78M
Officer · 20.00K sh · $3.60M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology